SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Syneos Health, Inc.
[March 19, 2019]

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Syneos Health, Inc.


Glancy Prongay & Murray LLP ("GPM") reminds investors of the April 30, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Syneos Health, Inc. ("Syneos Health" or the "Company") (NASDAQ: SYNH) securities between May 10, 2017 and February 27, 2019, inclusive (the "Class Period"). Syneos Health investors have until April 30, 2019 to file a lead plaintiff motion in this class action.

If you are a shareholder who suffered a loss, click here to participate.

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at a rel="nofollow" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.glancylaw.com&esheet=51957284&newsitemid=20190319005946&lan=en-US&anchor=www.glancylaw.com&index=4&md5=6e37cd5ec38bcb0d3f8b7160be25ad30">www.glancylaw.com.



On February 27, 2019, Syneos disclosed that the Securities and Exchange Commission ("SEC (News - Alert)") commenced an investigation into the Company's revenue accounting policies, internal controls and related matters, and requested that the Company retain certain documents for the periods beginning with January 1, 2017. On this news, Syneos' share price fell $10.31 or 19.8%, to close at $41.70 per share on February 28, 2019, thereby injuring investors.

The Complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Syneos Health's internal control over financial reporting was inadequate; (2) concerns regarding Syneos Health's internal control over financial reporting would result in heightened regulatory scrutiny and an SEC investigation into the company's revenue accounting policies, internal controls and related matters; and (3) as a result, defendants' statements about Syneos Health's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.


Follow us for updates on Twitter (News - Alert): twitter.com/GPM_LLP.

If you purchased or otherwise acquired Syneos Health securities during the Class Period you may move the Court no later than April 30, 2019 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2019 Technology Marketing Corporation. All rights reserved | Privacy Policy